TITLE

Perspective: Miles to go before we sleep

AUTHOR(S)
Rice, Charles
PUB. DATE
June 2011
SOURCE
Nature;6/9/2011 Supplement, Vol. 474 Issue 7350, pS8
SOURCE TYPE
Academic Journal
DOC. TYPE
Opinion
ABSTRACT
In this article, the author discusses the treatment of hepatitis C virus (HCV) infection using the newly developed drugs. He says that the new drugs which are inhibitors of NS3/4A protease must be combined with interferon- and ribavirin because the virus can overcome easily a single antiviral. He also mentions that people in the marginalized groups have higher risk of HCV, in which the availability of new treatment options can widen the gap between those who can afford and those who cannot.
ACCESSION #
61202557

 

Related Articles

  • Novel drugs in the management of difficult-to-treat hepatitis C genotypes. Cartwright, Emily J.; Miller, Lesley // Hepatic Medicine: Evidence & Research; 

    Background: Hepatitis C virus (HCV) infection is the most common chronic bloodborne infection in the United States, with approximately 3.2 million Americans being chronically infected. Rates of HCV-related end-stage liver disease and its associated morbidity and mortality have yet to peak, so...

  • Simeprevir for the treatment of hepatitis C virus infection. Izquierdo, Laure; Helle, François; François, Catherine; Castelain, Sandrine; Duverlie, Gilles; Brochot, Etienne // Pharmacogenomics & Personalized Medicine;Aug2014, Vol. 7, p241 

    Simeprevir (TMC435, Olysioâ„¢), a second-generation hepatitis C virus (HCV) protease inhibitor, has been recently approved for the treatment of genotype 1 chronic hepatitis C in combination with pegylated interferon and ribavirin. This molecule has very different characteristics from...

  • Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study. Hayashi, Norio; Mobashery, Niloufar; Izumi, Namiki // Journal of Gastroenterology;Feb2015, Vol. 50 Issue 2, p238 

    Background: Vaniprevir (MK-7009) is a hepatitis C virus (HCV) non-structural 3/4a protease inhibitor which significantly increases virologic response rates in HCV genotype (GT) 1-infected patients when added to peginterferon and ribavirin (PR). Methods: This was a phase II, multicenter,...

  • Telaprevir.  // Drugs in R&D;2010, Vol. 10 Issue 3, p179 

    Telaprevir (LY 570310; LY-570310; LY570310;MP 424;MP-424; VX 950; VX-950) is an orally administered peptidomimetic inhibitor of the hepatitis C virus (HCV) protease NS3/4A. It is being developed by Vertex Pharmaceuticals and its licensees for the treatment of HCV infections and has recently been...

  • New HCV treatments mean more patients to treat in France.  // PharmacoEconomics & Outcomes News;10/29/2011, Issue 640, p7 

    The article reports on a study which predicts that with the new combination therapy of peginterferon plus ribavirin and a protease inhibitor (PI), there will be a greater number of patients in France with genotype 1 (G1) hepatitis C virus (HCV) who will be treated than those receiving...

  • NICE recommends simeprevir for genotype 1 hepatitis C.  // PharmacoEconomics & Outcomes News;Sep2014, Vol. 712 Issue 1, p39 

    The article reports on the recommendation of the British public body National Institute of Clinical Excellence (NICE) regarding simeprevir drug, in combination with peginterferon α and ribavirin, as a treatment option for genotype 1 chronic hepatitis C in adult patients.

  • Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. Hoffmann, Luísa; Ramos, Juliene Antonio; de Souza, Elizabeth Valentin; de Araújo Ramos, Ana Lucia; Villela-Nogueira, Cristiane Alves; Ürményi, Turán Péter; Tanuri, Amilcar; Rondinelli, Edson; Silva, Rosane // Virology Journal;2013, Vol. 10 Issue 1, p1 

    About sixty thousand new cases of Hepatitis C virus (HCV) infection are recorded in Brazil each year. These cases are currently treated with pegylated interferon (PEG-IFN) and ribavirin (RBV) with an overall success rate of 50%. New compounds for anti-HCV therapy targeted to the HCV NS3 protease...

  • Kronik hepatit C tedavisinde yeni seçenekler. Demirtürk, Neşe // Genel Tip Dergisi;Dec2011, Vol. 21 Issue 4, p163 

    Objective: Chronic hepatitis C (CHC) is one of the important reasons of cirrhosis and hepatocellular carcinoma in the world. CHC patients should determine because of treatment of them may be prevent cirrhosis and hepatocellular carcinoma. Now, pegile-interferon 2a/2b and ribavirin combination is...

  • Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat? Petta, Salvatore; Crax�, Antonio // BMC Infectious Diseases;2012, Vol. 12 Issue Suppl 2, p1 

    The advent of triple therapy (TT) with first-generation protease inhibitors boceprevir (BOC) and telaprevir (TVR) in addition to pegylated interferon and ribavirin resulted in a significant gain in terms of sustained virological response (SVR) when treating naive or previous treated patients...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics